2020
DOI: 10.1002/jcla.23597
|View full text |Cite
|
Sign up to set email alerts
|

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes

Abstract: Background Myelodysplastic syndrome (MDS) is a heterogeneous clonal disease originated from hematopoietic stem cells. Epigenetic studies had demonstrated that DNA methylation and histone acetylation were abnormal in MDS. Azacitidine is an effective drug in the treatment of demethylation. Methods RT‐PCR was performed to determine GADD45γ in 15 MDS clinical samples. Myelodysplastic syndrome cell lines SKM‐1 and HS‐5 were transfected with GADD45γ eukaryotic expression vector and/or GADD45γ shRNA interference plas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
0
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 38 publications
0
0
0
Order By: Relevance
“…Azacitidine is a nucleoside metabolic inhibitor used to treat myelodysplastic syndrome (MDS) [1]. Azacitidine is a pyrimidine analog of the nucleoside cytidine [1].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Azacitidine is a nucleoside metabolic inhibitor used to treat myelodysplastic syndrome (MDS) [1]. Azacitidine is a pyrimidine analog of the nucleoside cytidine [1].…”
Section: Introductionmentioning
confidence: 99%
“…Azacitidine is a nucleoside metabolic inhibitor used to treat myelodysplastic syndrome (MDS) [1]. Azacitidine is a pyrimidine analog of the nucleoside cytidine [1]. It reversibly inhibits the enzymes DNA and RNA methyltransferase and subsequently blocks DNA and RNA methylation [1].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation